Relapsed and/or refractory acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal.
We previously reported that post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8
